MENU
+Compare
MBX
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$43.02
Change
+$6.71 (+18.48%)
Capitalization
1.63B

MBX MBX Biosciences Inc. Forecast, Technical & Fundamental Analysis

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders... Show more

MBX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for MBX with price predictions
Jan 13, 2026

MBX's Stochastic Oscillator reaches overbought zone

The Stochastic Oscillator for MBX moved into overbought territory on January 13, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for MBX moved out of overbought territory on December 23, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MBX broke above its upper Bollinger Band on January 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 12, 2026. You may want to consider a long position or call options on MBX as a result. In of 17 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MBX just turned positive on January 12, 2026. Looking at past instances where MBX's MACD turned positive, the stock continued to rise in of 11 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MBX advanced for three days, in of 84 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 31 cases where MBX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.207) is normal, around the industry mean (30.106). P/E Ratio (4.734) is within average values for comparable stocks, (51.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (322.270).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MBX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PIEFX21.86N/A
N/A
Federated Hermes Emerging Markets Eq IS
DISSX23.32-0.01
-0.04%
BNY Mellon Small Cap Stock Index Inv
HGIRX56.02-0.05
-0.09%
Hartford Core Equity R3
VSTCX44.15-0.09
-0.20%
Vanguard Strategic Small-Cap Equity Inv
RTDRX13.38-0.03
-0.22%
Russell Inv Multifactor US Equity R6

MBX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MBX has been loosely correlated with KOD. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MBX jumps, then KOD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBX
1D Price
Change %
MBX100%
-0.44%
KOD - MBX
47%
Loosely correlated
+0.93%
NEVPF - MBX
40%
Loosely correlated
N/A
NUVL - MBX
33%
Loosely correlated
+2.03%
RGNX - MBX
32%
Poorly correlated
-0.20%
FDMT - MBX
32%
Poorly correlated
+4.80%
More